Last updated 6 days ago
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
160 patients around the world
Available in Brazil, United States
Hoffmann-La Roche
1Research sites
160Patients around the world
This study is for people with
Dermatitis
Atopic dermatitis
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- AD diagnosis confirmed by a dermatologist according to the Hanifin/Rajka criteria at least 1 year prior to screening.Moderate to severe AD.At least once daily use of an additive-free, bland emollient for at least 7 days prior to the baseline visit and during the study.
- Evidence of other skin conditions that would interfere with the assessment of AD, including, but not limited to, for example cutaneous T-cell lymphoma, allergic contact dermatitis.IV, IM, IL, and oral corticosteroids (inhaled, ophthalmic drops, and nasal corticosteroids are allowed) within 4 weeks of the baseline visit and during the study.Topical treatment for AD including, but not limited to topical corticosteroids, topical calcineurin inhibitors, topical PDE-4 inhibitors, prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea or filaggrin within 7 days prior to the baseline visit and during the study.Any active infection or other active skin diseases that required treatment with parenteral anti-infectives within 4 weeks or oral anti-infective treatment within 2 weeks prior to baseline.Acquired or congenital immunodeficiency.Systemic therapies that are also used in the treatment of AD, including, but not limited to methotrexate, cyclosporine, azathioprine, mycophenolate mofetil within 4 weeks of the baseline visit and during the study.
Sites
Instituto Brasil de Pesquisa Clínica - IBPClin
Recruiting
SponsorHoffmann-La Roche
Study typeInterventional
Conditions
Atopic dermatitis
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06863961
